Amylyx Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joshua Cohen
- Full Time Employees
- 136
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 43 Thorndike Street Cambridge MA United States of America 02141
- IPO Date
- Jan 7, 2022
- CIK
- 0001658551
- Website
- amylyx.com
- Similar Companies
- Business
- Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize novel therapies addressing high unmet needs in neurodegenerative and endocrine diseases. Founded in 2013 and headquartered at 43 Thorndike Street in Cambridge, Massachusetts, the company advances a pipeline of investigational therapies including its lead candidate avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI), both of which carry FDA Breakthrough Therapy and Orphan Drug Designations; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol targeting endoplasmic reticulum stress and mitochondrial dysfunction for Wolfram syndrome and progressive supranuclear palsy (PSP); and AMX0114, an antisense oligonucleotide inhibiting calpain-2 for amyotrophic lateral sclerosis (ALS), which holds FDA Fast Track Designation. Amylyx operates globally through subsidiaries such as Amylyx Pharmaceuticals Canada Inc. in Calgary, Amylyx Pharmaceuticals Japan K.K., and Amylyx Pharmaceuticals EMEA B.V. in Amsterdam, targeting patient communities in the United States, Canada, Europe and Japan. Recent developments include the July 2024 acquisition of avexitide from Eiger BioPharmaceuticals for $35.1 million plus assumed liabilities and royalties, initiation of the Phase 3 LUCIDITY trial in PBH with first patient dosed in April 2025 and recruitment completion expected in Q1 2026 yielding topline data in Q3 2026, positive Week 48 data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome in May 2025 supporting a planned pivotal Phase 3 start in H2 2026 pending FDA alignment, full enrollment of Phase 1 LUMINA cohort 1 for AMX0114 in ALS in September 2025 with early data presentation at the December 2025 International Symposium on ALS/MND, a December 2024 collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist advancing toward a potential development candidate decision soon, and a September 2025 public offering raising approximately $191 million to extend cash runway into 2028 through avexitide's potential 2027 launch if approved.
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. – AMLX
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC
Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
Amylyx Pharmaceuticals Q4 Earnings Call Highlights